[Endovascular treatment for venous malformations with three-point anhydrous ethanol injection].
OBJECTIVE
To explore the safe method with anhydrous ethanol injection in the treatment of venous malformation.


METHODS
A total of 96 patients with venous malformation were conducted anhydrous ethanol injection for 245 times through percutaneous puncture by three-point method. The complications were observed. In animal experiment, according to the different concentrations of anhydrous ethanol injection, rats were divided into an anhydrous ethanol group, a 75% ethanol group, a 50% ethanol group and a 25% ethanol group (n=5 in each group), and the damage of vessels after ethanol injection was observed.


RESULTS
The successful rate for three-point ethanol injection was 88%. The incidence for both skin ulcer and numbness was 0.9% without severe complications in lung and heart. In the animal experiments, the entire vessel wall including outer membrane was damaged in the anhydrous ethanol group. Part of vessel walls, including the inner membrane and muscle layer, were damaged in both the 75% ethanol group and the 50% ethanol group. However, there was no damage in the vessels in the 25% ethanol group.


CONCLUSIONS
With the decrease in ethanol concentration, the vascular damage is decreased and eventually disappeared. Three-point anhydrous ethanol injection is safe and effective.
Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Qizhen
Q
Wu
Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Jiaguang
J
Li
Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Shaorong
S
Lei
Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Wuyuan
W
Tan
Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.
Jianhong
J
Long
D000818:Animals; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007267:Injections / Q000379:methods; D051381:Rats; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D015911:Sclerotherapy; D054079:Vascular Malformations / Q000628:therapy*
D012597:Sclerosing Solutions; D000431:Ethanol